India’s first indigenously developed Quadrivalent Human Papillomavirus vaccine (qHPV) against cervical cancer is set to be launched on September 1. According to official sources, the vaccine will be launched by the Serum Institute of India (SII) and the Department of Biotechnology (DBT).
The event will be honoured by Union Minister of State (Independent Charge) Science & Technology Jitendra Singh.
As per the data of the World Health Organisation (WHO), in 2018, an estimated 570 000 women were diagnosed with cervical cancer worldwide and about 311 000 women died from the disease.
Majority of cervical cancer is due to human papillomavirus. Two human papillomavirus (HPV) types (16 and 18) are responsible for nearly 50% of high grade cervical pre-cancers.
